The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Prostate kallikrein markers in diagnosis, risk stratification and prognosis.

På svenska

Author

Summary, in English

The kallikrein, prostate-specific antigen (PSA), is one of the world's most frequently used disease biomarkers. After almost two decades of research and clinical experience, the diagnostic and monitoring limitations of PSA are beginning to be understood. Most physicians are aware of PSA's low specificity for cancer among older men with benign prostatic conditions; fewer are aware of recent data, which show that a prior negative biopsy or a prior PSA value below the threshold for biopsy might compromise the predictive accuracy of PSA even further. Furthermore, a subtle increase in serum PSA level during early middle age is strongly correlated with clinically important prostate cancer. We review current and past reports on the prostate kallikreins PSA and hK2 in relation to pathology and epidemiology.

Publishing year

2009

Language

English

Pages

384-391

Publication/Series

Nature Reviews Urology

Volume

6

Issue

7

Document type

Journal article

Publisher

Nature Publishing Group

Topic

  • Cancer and Oncology
  • Urology and Nephrology
  • Medicinal Chemistry

Status

Published

Research group

  • Clinical Chemistry, Malmö
  • Urological cancer, Malmö

ISBN/ISSN/Other

  • ISSN: 1759-4820